Real life evaluation of safinamide effectiveness in Parkinson’s disease
- 181 Downloads
In this retrospective study, we evaluated both efficacy and effectiveness of safinamide 50 and 100 mg in the treatment of motor fluctuations and disabling dyskinesias in a cohort of patients with idiopathic Parkinson’s disease (PD). Ninety-one PD patients were evaluated during the first year of commercialization of the drug, both prior to starting safinamide and at the last available follow-up. Evaluations were based on the Unified Parkinson’s Disease Scale part III (UPDRS III), Hoehn & Yahr (HY), Unified Dyskinesia Rating Scale (UDysRS) walking and balance item 9 score, daily time spent in OFF and in ON with disabling dyskinesias (1 week diary), mean daily dose of levodopa (LD), dopamine-agonists (DA), catechol-O-methyl transferase inhibitor (COMT-I), monoamine oxidase B inhibitor (MAOB-I), and their LD equivalent dose (LEDD). Eight patients withdrew safinamide within the first month for minor side effects. At the follow-up evaluation, after a mean time with safinamide of 7.5 months ± 3.4, all patients showed a significant improvement of all the scale scores, except for HY, and of the daily dosages of the drugs and the LEDD. The same results were shown by PD patients treated with safinamide 50 mg and patients who started safinamide without switching from a previous MAOBI. PD patients with safinamide 100 mg and patients who started safinamide switching from a previous MAOBI significantly improved in time spent in OFF and LEDD. In conclusion, safinamide is safe and effective in improving motor complications in patients with idiopathic PD and can be considered a useful levodopa sparing strategy.
KeywordsParkinson’s disease Motor fluctuations Dyskinesias Safinamide
We thank Maggie Dufresne for the linguistic revision of the text and the patients and their caregivers for the collaboration.
Compliance with ethical standards
Conflict of interests
Francesca Mancini has received speaker honoraria from Zambon and Abbvie.
Alessio Di Fonzo has received a speaker honorarium from Sanofi Genzyme.
Giulia Lazzeri has no conflict of interest.
Linda Borellini has no conflict of interest.
Vincenzo Silani serves on the Board of Cytokinetics for the Vitality trial in ALS and he received consulting fees.
Marco Lacerenza has received speaker honoraria from Mundipharma.
Cristoforo Comi has received financial support (including research funding and speaker honoraria) from Lundbeck, Chiesi, UCB, Zambon, and Abbvie.
All authors have participated in the research and/or article preparation.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study formal consent is not required.
- 5.Cilia R, Akpalu A, Sarfo FS, Cham M, Amboni M, Cereda E, Fabbri M, Adjei P, Akassi J, Bonetti A, Pezzoli G (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(10):2731–2742. https://doi.org/10.1093/brain/awu195 CrossRefPubMedPubMedCentralGoogle Scholar
- 6.Pevarello P, Traquandi G, Bonsignori A, McArthur RA, Maj R, Caccia C, Salvati P, Varasi M (1999) Synthesis and preliminary biological evaluation of new alpha-amino amide anticonvulsants incorporating a dextromethorphan moiety. Bioorg Med Chem Lett 9(13):1783–1788. https://doi.org/10.1016/S0960-894X(99)00271-1 CrossRefPubMedGoogle Scholar
- 7.Salvati P, Maj R, Caccia C, Cervini MA, Fornaretto MG, Lamberti E, Pevarello P, Skeen GA, White HS, Wolf HH, Faravelli L, Mazzanti M, Mancinelli E, Varasi M, Fariello RG (1999) Biochemical and electrophysiological studies on the mechanism of action of PNU-151774E, a novel antiepileptic compound. J Pharmacol Exp Ther 288(3):1151–1159PubMedGoogle Scholar
- 10.Olanow CW, Stocchi F (2016) Safinamide—a new therapeutic option to address motor symptoms and motor complications in mid-to-late stage Parkinson’s disease. Eur Neurol Rev 11(Suppl 2):2–15Google Scholar
- 14.Schapira AH, Fox SH, Hauser RA, Jankovic J, Jost WH, Kenney C, Kulisevsky J, Pahwa R, Poewe W, Anand R (2017) Assessment of safety and efficacy of safinamide as a levodopa adjunct in patients with Parkinson disease and motor fluctuations. A randomized clinical trial. JAMA Neurol 74(2):216–224. https://doi.org/10.1001/jamaneurol.2016.4467 CrossRefPubMedGoogle Scholar
- 15.Borgohain R, Szasz J, Stanzione P, Meshram C, Bhatt M, Chirilineau D, Stocchi F, Lucini V, Giuliani R, Forrest E, Rice P, Anand R, Study 016 Investigators (2014) Randomized trial of safinamide add-on to levodopa in Parkinson's disease with motor fluctuations. Mov Disord 29(2):229–237. https://doi.org/10.1002/mds.25751 CrossRefPubMedGoogle Scholar